Danaher’s Q2 2026: A Masimo-Driven Lift to EPS and a Quiet Confidence in Life Sciences

Key numbers at a glance

Danaher reported second-quarter 2026 net earnings of $870 million, or $1.23 per diluted share, up 60% year over year. Non-GAAP diluted earnings per share rose 8.0% to $1.94. Revenue came in at $6.3 billion, up 5.5% from a year earlier. Non-GAAP core revenue grew 3.0% year over year, and non-GAAP core revenue excluding respiratory testing revenue grew 4.5%.

Operating cash flow was $1.5 billion, with non-GAAP free cash flow of $1.3 billion. Management highlighted that the Masimo acquisition’s earlier-than-expected completion supports a higher full-year non-GAAP diluted EPS outlook.

CEO Rainer M. Blair framed the quarter as better than anticipated, with Life Sciences delivering momentum and bioprocessing orders rising in the mid-teens, even as project timing in that segment tempered revenue in the near term.

Note: The release does not provide a formal EPS consensus figure in the headline disclosures. The company emphasizes non-GAAP metrics and cautions on reconciliation to GAAP due to acquisition-related amortization and currency effects. The headline takeaway for investors remains the trajectory of EPS and the implied growth of the revenue base.

Guidance and what it implies for the year

For the third quarter of 2026, Danaher expects non-GAAP core revenue to rise 2.0% to 3.0% year over year. For the full year 2026, the company now projects non-GAAP core revenue growth of 3.0% to 4.0% year over year. Correspondingly, it raised its full-year adjusted diluted EPS guidance to a range of $8.45 to $8.60, up from the prior $8.35 to $8.55.

The guidance incorporates the anticipated currency effects and the impact of acquisition-related intangible amortization. Management quantified an estimated currency impact that could reduce third-quarter sales by about 1.0% and move full-year sales higher by roughly 0.5%, under the currency rates in effect as of June 26, 2026. The company also notes that non-GAAP forecasts are not reconciled to GAAP measures in full detail because certain amortization and other items are difficult to predict.

What this means for Danaher and its peers

The Masimo deal is no longer a teaser; it’s a live driver of the earnings narrative. Management frames the acquisition as a capability to accelerate full-year EPS growth and cash generation, suggesting potential accretion to margins as the integration progresses and revenue streams diversify. In practice, investors should watch for how much of the near-term uplift in non-GAAP earnings translates into GAAP results as one-time amortization winds down and synergies materialize.

From a sector perspective, Danaher’s resilience in Life Sciences—the segment that delivered the strongest momentum in several years—points to continued demand in bioprocessing and related tools. The mid-teens growth in bioprocessing orders signals a healthy underlying demand backdrop, though project timing remains a seasonally sensitive factor. Peers with heavier exposure to biopharma manufacturing or diagnostic instrumentation may see similar dynamics: solid top-line growth, tempered by mix effects and integration costs from recent acquisitions.

In short, the quarter reinforces a familiar script for Danaher: disciplined cost management, ongoing cash generation, and a strategic M&A tailwind that could lift longer-term equity value. The non-GAAP emphasis remains a practical lens through which investors evaluate performance in an environment where currency swings and acquisition-related costs can obscure GAAP comparability.

Conference call and investor materials

Danaher will discuss second-quarter results and the 2026 outlook during its investor conference call at 8:00 a.m. ET. The call and an accompanying slide deck will be webcast in the Investors section of the company’s website, www.danaher.com. A replay will be available after the session and remain accessible through the next earnings cycle.

Bottom line

Danaher’s Q2 report reinforces a narrative of strength in core life sciences franchises, aided by a strategic acquisition that’s already reflected in higher earnings guidance. With EPS progression, a broader revenue footprint, and solid cash flow, the stock’s near-term path may hinge on whether the company sustains its growth cadence through the second half of 2026 and how currency and integration dynamics shape GAAP-versus-non-GAAP results. For investors and sector peers alike, the message is clear: the core engine remains powered, and the balance sheet has a new lever to pull.